RELAPSING REMITTING MULTIPLE SCLEROSIS

This study looked at the safety of Kesimpta, a drug for relapsing-remitting and active secondary progressive multiple sclerosis. It included 367 people who were using the drug for the first time. Researchers tracked any side effects or serious medical events that happened during …

This study tested an oral medication called PIPE-307 in 182 adults with relapsing-remitting multiple sclerosis (MS). Participants took either a low dose, a high dose, or a placebo pill for about 30 weeks. The main goals were to check for side effects and measure changes in vision…

This study looked at blood samples from 40 people with relapsing-remitting multiple sclerosis (MS) before and after 6 months of treatment with ofatumumab (Kesimpta). Researchers tested whether immune cells from treated patients were less harmful to mouse brain cells grown in a la…

This study looked at whether virtual reality (VR) tasks, like driving or shopping in a virtual store, can detect thinking and attention problems in people with relapsing-remitting multiple sclerosis (MS) better than standard paper-and-pencil tests. Sixty adults with MS and health…

This study tested a special eye-imaging technique called adaptive optics to look at blood vessel changes in the retina of people with multiple sclerosis (MS). Researchers measured swelling around retinal vessels in 50 participants with different MS types and compared them to heal…

This study looked at 58 people, including those with typical and atypical multiple sclerosis (MS) and healthy controls, to see if blood markers of nerve damage could help tell these conditions apart. Researchers measured two proteins in the blood: neurofilament light chain and GF…

This study looked at how the COVID-19 pandemic changed the way multiple sclerosis (MS) relapses were reported and managed. Researchers compared 51 patients who had a relapse during the first wave of the pandemic (April-June 2020) to those who had a relapse during the same months …